Metformin side effects: what 354,745 FDA adverse event reports show
Drug class
Not stated in label
Brand names
Metformin Hydrochloride
Who reports
354,745 reports · 69% serious · 29,950 with death outcome · 54% female
Used for
Metformin hydrochloride extended-release tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Metformin hydrochloride extended-release tablets are a biguanide indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1 )
What it is
Metformin is a member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1. It has a role as a geroprotector, a hypoglycemic agent, a xenobiotic and an environmental contaminant.
Boxed warning
LACTIC ACIDOSIS Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin-associated lactic acidosis is often subtle, accompanied only by nonspecific symptoms such as malaise, myalgias, respiratory distress, somnolence, and abdominal pain.
Causality screen of the 40 strongest signals
What the badges mean
- Labeled — boxed warning The term (or its clinical synonym) appears in the FDA boxed warning: causality is regulator-recognised and considered serious.
- Labeled adverse reaction The exact term appears in the label's warnings or adverse-reactions sections: a known, expected effect. The FAERS signal confirms the label rather than discovering anything.
- Labeled (related wording) The label describes this effect under different wording (e.g. 'neutropenia' for 'neutrophil count decreased'). Treated as known.
- Likely indication confounding The term appears in the label's indications: reports probably describe the disease being treated (or its progression), not a drug effect. Classic confounding by indication.
- Reporting / coding artifact An administrative, monitoring or exposure term (product issue, off-label use, 'test normal', overdose...). Not a biological reaction; a high PRR here reflects how reports are coded.
- Lab value / disease marker A laboratory result, investigation or disease-activity marker (antibody positive, CRP abnormal, swollen joint count) not described in the label. These usually mirror the monitored disease or testing protocol rather than a drug effect; not screened further.
- Not in label — unassessed Not found in the label text, not an artifact pattern. This is a genuine candidate for a formal causality assessment (Bradford Hill / WHO-UMC); it has NOT had one here.
Strongest disproportionality signals
Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,113 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Lactic acidosis | 17,141 | 67.6 66.2–69.1ROR 71.0 · calibrated p 1e-6 ✓ | 31.6 EB05 31.2 · IC025 +5.0 3/3 methods agree | Labeled — boxed warning exact term | age-adj. PRR 53.5 · serious PRR 26.4 · 96% clinician | no trial arm names this drug |
| Neurologic neglect syndrome | 289 | 62.7 53.1–74.1ROR 62.8 · calibrated p 4e-6 ✓ | 30.4 EB05 27.6 · IC025 +4.7 3/3 methods agree | Not in label — unassessed | serious n=289 · ♀ 100% (drug 54%) · 100% clinician | no trial arm names this drug |
| Euglycaemic diabetic ketoacidosis | 1,754 | 46.1 43.3–49.1ROR 46.3 · calibrated p 2e-5 ✓ | 26.0 EB05 25.0 · IC025 +4.6 3/3 methods agree | Labeled (related wording) related wording | serious n=1,749 · 95% clinician | no trial arm names this drug |
| Pulmonary vasculitis | 226 | 43.8 36.8–52.0ROR 43.8 · calibrated p 3e-5 ✓ | 25.2 EB05 22.6 · IC025 +4.4 3/3 methods agree | Not in label — unassessed | serious n=226 · ♀ 0% (drug 54%) · 100% clinician | no trial arm names this drug |
| Carotid artery thrombosis | 296 | 31.0 26.9–35.7ROR 31.0 · calibrated p 2e-4 ✓ | 20.5 EB05 18.6 · IC025 +4.1 3/3 methods agree | Not in label — unassessed | serious n=296 · ♀ 100% (drug 54%) · 100% clinician | no trial arm names this drug |
| Diabetic metabolic decompensation | 469 | 29.9 26.8–33.5ROR 30.0 · calibrated p 3e-4 ✓ | 20.0 EB05 18.5 · IC025 +4.1 3/3 methods agree | Labeled (related wording) related wording | serious n=469 | no trial arm names this drug |
| Hyperlactacidaemia | 804 | 25.6 23.6–27.8ROR 25.7 · calibrated p 6e-4 ✓ | 18.0 EB05 17.0 · IC025 +4.0 3/3 methods agree | Not in label — unassessed | serious n=804 · 100% clinician | no trial arm names this drug |
| Adjustment disorder | 301 | 17.5 15.4–19.9ROR 17.5 · calibrated p 0.004 ✓ | 13.6 EB05 12.4 · IC025 +3.5 3/3 methods agree | Not in label — unassessed | serious n=299 · ♀ 100% (drug 54%) · 100% clinician | no trial arm names this drug |
| Metabolic acidosis | 6,200 | 14.2 13.8–14.6ROR 14.4 · calibrated p 0.008 ✓ | 11.6 EB05 11.3 · IC025 +3.5 3/3 methods agree | Labeled adverse reaction exact term | age-adj. PRR 13.0 · serious PRR 9.7 · 94% clinician | no trial arm names this drug |
| Anion gap increased | 243 | 12.9 11.2–14.8ROR 12.9 · calibrated p 0.013 ✓ | 10.6 EB05 9.5 · IC025 +3.2 3/3 methods agree | Labeled (related wording) related wording | serious n=239 · ♀ 0% (drug 54%) · 100% clinician | no trial arm names this drug |
| Glycosylated haemoglobin increased | 4,539 | 12.8 12.4–13.2ROR 13.0 · calibrated p 0.013 ✓ | 10.6 EB05 10.4 · IC025 +3.4 3/3 methods agree | Lab value / disease marker | serious PRR 9.6 | no trial arm names this drug |
| Ketoacidosis | 1,347 | 12.8 12.1–13.6ROR 12.8 · calibrated p 0.013 ✓ | 10.6 EB05 10.2 · IC025 +3.3 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 8.9 | no trial arm names this drug |
| Glycosylated haemoglobin abnormal | 210 | 12.6 10.8–14.6ROR 12.6 · calibrated p 0.015 ✓ | 10.4 EB05 9.3 · IC025 +3.1 3/3 methods agree | Lab value / disease marker | ♀ 0% (drug 54%) · 100% consumer | no trial arm names this drug |
| Hypoglycaemic coma | 508 | 12.4 11.3–13.7ROR 12.4 · calibrated p 0.015 ✓ | 10.3 EB05 9.6 · IC025 +3.2 3/3 methods agree | Not in label — unassessed | serious n=508 · 100% clinician | no trial arm names this drug |
| Gastrointestinal hypomotility | 384 | 12.1 10.8–13.5ROR 12.1 · calibrated p 0.016 ✓ | 10.1 EB05 9.3 · IC025 +3.2 3/3 methods agree | Not in label — unassessed | serious n=380 · 100% consumer | no trial arm names this drug |
| Diabetic ketoacidosis | 4,053 | 11.9 11.5–12.3ROR 12.0 · calibrated p 0.017 ✓ | 10.0 EB05 9.7 · IC025 +3.3 3/3 methods agree | Labeled adverse reaction exact term | age-adj. PRR 13.2 · serious PRR 8.4 | no trial arm names this drug |
| Diabetes mellitus inadequate control | 2,895 | 11.4 10.9–11.8ROR 11.5 · calibrated p 0.020 ✓ | 9.7 EB05 9.4 · IC025 +3.2 3/3 methods agree | Labeled (related wording) related wording | serious PRR 8.3 | no trial arm names this drug |
| Vitamin b12 deficiency | 630 | 10.8 9.9–11.8ROR 10.8 · calibrated p 0.025 ✓ | 9.2 EB05 8.6 · IC025 +3.1 3/3 methods agree | Labeled (related wording) related wording | serious n=589 | no trial arm names this drug |
| Glycosylated haemoglobin decreased | 243 | 10.5 9.1–12.0ROR 10.5 · calibrated p 0.028 ✓ | 8.9 EB05 8.0 · IC025 +2.9 3/3 methods agree | Lab value / disease marker | 100% consumer | no trial arm names this drug |
| Hypoglycaemia (low blood sugar) | 7,287 | 10.3 10.0–10.5ROR 10.5 · calibrated p 0.027 ✓ | 8.9 EB05 8.7 · IC025 +3.1 3/3 methods agree | Labeled — boxed warning exact term | age-adj. PRR 8.7 · serious PRR 7.8 | no trial arm names this drug |
| Neuritis | 227 | 10.1 8.7–11.6ROR 10.1 · calibrated p 0.032 ✓ | 8.6 EB05 7.7 · IC025 +2.9 3/3 methods agree | Not in label — unassessed | serious n=225 · ♀ 0% (drug 54%) · 100% clinician | no trial arm names this drug |
| Blood lactic acid increased | 724 | 9.3 8.6–10.1ROR 9.3 · calibrated p 0.041 ✓ | 8.1 EB05 7.6 · IC025 +2.9 3/3 methods agree | Lab value / disease marker | serious n=703 · 100% clinician | no trial arm names this drug |
| Distributive shock | 305 | 9.3 8.3–10.5ROR 9.3 · calibrated p 0.041 ✓ | 8.1 EB05 7.3 · IC025 +2.8 3/3 methods agree | Not in label — unassessed | serious n=305 · 100% clinician | no trial arm names this drug |
| Impaired gastric emptying | 1,751 | 9.3 8.8–9.7ROR 9.3 · calibrated p 0.041 ✓ | 8.1 EB05 7.8 · IC025 +2.9 3/3 methods agree | Not in label — unassessed | serious PRR 7.3 · 87% consumer | no trial arm names this drug |
| Diabetic neuropathy | 670 | 9.0 8.3–9.8ROR 9.1 · calibrated p 0.045 ✓ | 7.9 EB05 7.4 · IC025 +2.9 3/3 methods agree | Likely indication confounding shares a disease stem with the indications wording | serious n=572 | no trial arm names this drug |
| Personality disorder | 345 | 8.8 7.8–9.8ROR 8.8 · calibrated p 0.051 | 7.7 EB05 7.0 · IC025 +2.8 3/3 methods agree | Not in label — unassessed | serious n=341 · ♀ 100% (drug 54%) · 100% clinician | no trial arm names this drug |
| Blood bicarbonate decreased | 245 | 8.6 7.5–9.8ROR 8.6 · calibrated p 0.055 | 7.5 EB05 6.7 · IC025 +2.7 3/3 methods agree | Lab value / disease marker | serious n=244 · ♀ 0% (drug 54%) · 100% clinician | no trial arm names this drug |
| Suspected suicide | 578 | 8.0 7.4–8.8ROR 8.0 · calibrated p 0.066 | 7.1 EB05 6.7 · IC025 +2.7 3/3 methods agree | Not in label — unassessed | serious n=578 · 100% clinician | no trial arm names this drug |
| Hyperparathyroidism secondary | 295 | 7.7 6.8–8.7ROR 7.7 · calibrated p 0.076 | 6.8 EB05 6.2 · IC025 +2.6 3/3 methods agree | Not in label — unassessed | serious n=295 | no trial arm names this drug |
| Blood pressure diastolic abnormal | 298 | 7.6 6.8–8.6ROR 7.6 · calibrated p 0.078 | 6.8 EB05 6.2 · IC025 +2.6 3/3 methods agree | Lab value / disease marker | serious n=295 · ♀ 100% (drug 54%) · 100% clinician | no trial arm names this drug |
| Nephrogenic anaemia | 536 | 7.5 6.9–8.2ROR 7.5 · calibrated p 0.080 | 6.7 EB05 6.3 · IC025 +2.6 3/3 methods agree | Not in label — unassessed | serious n=536 | no trial arm names this drug |
| Diabetic retinopathy | 389 | 7.5 6.8–8.4ROR 7.5 · calibrated p 0.081 | 6.7 EB05 6.2 · IC025 +2.6 3/3 methods agree | Likely indication confounding shares a disease stem with the indications wording | serious n=358 | no trial arm names this drug |
| Blood glucose fluctuation | 1,248 | 7.5 7.0–7.9ROR 7.5 · calibrated p 0.082 | 6.7 EB05 6.4 · IC025 +2.6 3/3 methods agree | Lab value / disease marker | serious n=697 | no trial arm names this drug |
| Acute kidney injury (sudden kidney damage) | 17,231 | 7.4 7.3–7.5ROR 7.7 · calibrated p 0.073 | 6.7 EB05 6.6 · IC025 +2.7 3/3 methods agree | Labeled — boxed warning synonym match | age-adj. PRR 6.0 · serious PRR 5.6 | no trial arm names this drug |
| Hyperkalaemia (high potassium) | 3,924 | 7.4 7.1–7.6ROR 7.4 · calibrated p 0.083 | 6.6 EB05 6.5 · IC025 +2.7 3/3 methods agree | Not in label — unassessed | age-adj. PRR 5.6 · serious PRR 5.7 · 93% clinician | no trial arm names this drug |
| Blood glucose abnormal | 2,060 | 7.3 7.0–7.6ROR 7.3 · calibrated p 0.087 | 6.6 EB05 6.3 · IC025 +2.6 3/3 methods agree | Lab value / disease marker | serious PRR 6.4 | no trial arm names this drug |
| Insulin resistance | 228 | 7.3 6.3–8.4ROR 7.3 · calibrated p 0.089 | 6.5 EB05 5.8 · IC025 +2.5 3/3 methods agree | Reporting / coding artifact | ♀ 100% (drug 54%) · 100% consumer | no trial arm names this drug |
| Forced expiratory volume decreased | 294 | 6.7 6.0–7.6ROR 6.7 · calibrated p 0.111 | 6.1 EB05 5.5 · IC025 +2.4 3/3 methods agree | Lab value / disease marker | serious n=294 · ♀ 0% (drug 54%) | no trial arm names this drug |
| Pancreatic carcinoma metastatic | 287 | 6.5 5.7–7.3ROR 6.5 · calibrated p 0.123 | 5.9 EB05 5.3 · IC025 +2.4 3/3 methods agree | Not in label — unassessed | serious n=287 · 100% clinician | no trial arm names this drug |
| Drug level above therapeutic | 452 | 6.4 5.8–7.1ROR 6.4 · calibrated p 0.126 | 5.8 EB05 5.4 · IC025 +2.4 3/3 methods agree | Reporting / coding artifact | serious n=452 · 100% clinician | no trial arm names this drug |
Clinical concept groups
MedDRA splits one clinical problem across several terms (e.g. "neutropenia", "neutrophil count decreased", "agranulocytosis"), which dilutes term-level signals. These rows count reports with any term in a concept group (an exact union, not a sum), compared with all other drugs. Groups are hand-built and listed in the methods.
| Concept | Reports | PRR 95% CI | Reading |
|---|---|---|---|
| Hypoglycaemia | 11,623 | 8.07.9–8.2 | signal |
| Hyperglycaemia / diabetes | 32,267 | 6.05.9–6.0 | signal |
| Kidney injury | 28,656 | 3.93.8–3.9 | signal |
| Pancreatitis | 4,597 | 3.53.4–3.6 | signal |
| Hyponatraemia | 2,920 | 2.22.1–2.3 | signal |
| Rhabdomyolysis / myopathy | 2,877 | 2.12.1–2.2 | signal |
| Arrhythmia / qt | 5,665 | 1.81.7–1.8 | raised |
| Gi bleeding | 5,288 | 1.71.7–1.8 | raised |
| Heart failure | 4,844 | 1.61.6–1.7 | raised |
| Fall / fracture | 10,240 | 1.61.6–1.6 | raised |
| Suicidality | 6,352 | 1.51.5–1.6 | raised |
| Myocardial infarction | 5,252 | 1.51.5–1.6 | raised |
| Anaemia | 7,523 | 1.51.5–1.5 | raised |
| Serious infection | 18,632 | 1.41.4–1.5 | raised |
| Stroke | 5,832 | 1.41.4–1.4 | raised |
| Liver injury | 6,778 | 1.31.3–1.4 | raised |
Trial evidence (ClinicalTrials.gov)
Most frequently reported reactions
By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Diarrhoea (diarrhea) | 22,969 | 2.2 2.1–2.2ROR 2.2 · calibrated p 0.936 | 2.1 EB05 2.1 · IC025 +1.1 3/3 methods agree | Labeled adverse reaction exact term | age-adj. PRR 1.8 · serious PRR 2.0 | no trial arm names this drug |
| Nausea | 22,945 | 1.7 1.7–1.8ROR 1.8 · calibrated p 0.825 | 1.7 EB05 1.7 · IC025 +0.8 | Labeled adverse reaction exact term | age-adj. PRR 1.6 · serious PRR 1.7 | no trial arm names this drug |
| Drug ineffective (drug did not work) | 18,951 | 0.8 0.8–0.9ROR 0.8 · calibrated p 0.207 | 0.9 EB05 0.8 · IC025 -0.3 PRR-only: not supported by EBGM or IC | Reporting / coding artifact | age-adj. PRR 1.0 · serious PRR 1.0 | no trial arm names this drug |
| Blood glucose increased | 18,631 | 6.4 6.3–6.4ROR 6.7 · calibrated p 0.114 | 5.8 EB05 5.7 · IC025 +2.5 3/3 methods agree | Lab value / disease marker | age-adj. PRR 4.8 · serious PRR 5.1 · 78% consumer | no trial arm names this drug |
| Fatigue (tiredness) | 17,926 | 1.4 1.4–1.4ROR 1.4 · calibrated p 0.570 | 1.4 EB05 1.3 · IC025 +0.4 | Not in label — unassessed | age-adj. PRR 1.2 · serious PRR 1.4 | no trial arm names this drug |
| Acute kidney injury (sudden kidney damage) | 17,231 | 7.4 7.3–7.5ROR 7.7 · calibrated p 0.073 | 6.7 EB05 6.6 · IC025 +2.7 3/3 methods agree | Labeled — boxed warning synonym match | age-adj. PRR 6.0 · serious PRR 5.6 | no trial arm names this drug |
| Lactic acidosis | 17,141 | 67.6 66.2–69.1ROR 71.0 · calibrated p 1e-6 ✓ | 31.6 EB05 31.2 · IC025 +5.0 3/3 methods agree | Labeled — boxed warning exact term | age-adj. PRR 53.5 · serious PRR 26.4 · 96% clinician | no trial arm names this drug |
| Vomiting | 15,555 | 2.0 2.0–2.0ROR 2.0 · calibrated p 0.966 | 2.0 EB05 1.9 · IC025 +0.9 | Labeled adverse reaction exact term | age-adj. PRR 2.0 · serious PRR 1.9 | no trial arm names this drug |
| Off label use (used outside approved label) | 14,124 | 1.0 0.9–1.0ROR 1.0 · calibrated p 0.280 | 1.0 EB05 0.9 · IC025 -0.1 PRR-only: not supported by EBGM or IC | Reporting / coding artifact | age-adj. PRR 0.9 · serious PRR 1.1 | no trial arm names this drug |
| Dyspnoea (shortness of breath) | 14,041 | 1.5 1.5–1.5ROR 1.5 · calibrated p 0.641 | 1.5 EB05 1.4 · IC025 +0.5 | Not in label — unassessed | age-adj. PRR 1.3 · serious PRR 1.4 | no trial arm names this drug |
| Dizziness | 12,638 | 1.5 1.5–1.5ROR 1.5 · calibrated p 0.663 | 1.5 EB05 1.5 · IC025 +0.6 | Labeled adverse reaction exact term | age-adj. PRR 1.3 · serious PRR 1.5 | no trial arm names this drug |
| Headache | 12,459 | 1.2 1.2–1.2ROR 1.2 · calibrated p 0.430 | 1.2 EB05 1.2 · IC025 +0.2 | Labeled adverse reaction exact term | age-adj. PRR 1.1 · serious PRR 1.3 | no trial arm names this drug |
| Weight decreased (weight loss) | 12,317 | 2.7 2.6–2.7ROR 2.7 · calibrated p 0.715 | 2.6 EB05 2.6 · IC025 +1.4 3/3 methods agree | Not in label — unassessed | age-adj. PRR 2.2 · serious PRR 2.1 | no trial arm names this drug |
| Pain | 12,051 | 1.2 1.1–1.2ROR 1.2 · calibrated p 0.417 | 1.2 EB05 1.1 · IC025 +0.2 | Labeled — boxed warning exact term | age-adj. PRR 1.3 · serious PRR 1.1 | no trial arm names this drug |
| Asthenia (weakness) | 10,878 | 1.7 1.7–1.8ROR 1.8 · calibrated p 0.802 | 1.7 EB05 1.7 · IC025 +0.7 | Not in label — unassessed | age-adj. PRR 1.4 · serious PRR 1.6 | no trial arm names this drug |
Unlabeled candidate signals
These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.
- Neurologic neglect syndrome — n=289, PRR 62.7
- Pulmonary vasculitis — n=226, PRR 43.8
- Carotid artery thrombosis — n=296, PRR 31.0
- Hyperlactacidaemia — n=804, PRR 25.6
- Adjustment disorder — n=301, PRR 17.5
- Hypoglycaemic coma — n=508, PRR 12.4
- Gastrointestinal hypomotility — n=384, PRR 12.1
- Neuritis — n=227, PRR 10.1
- Distributive shock — n=305, PRR 9.3
- Impaired gastric emptying — n=1,751, PRR 9.3
✓ A hand-written Bradford Hill causality assessment exists for this drug: Metformin ↔ Lactic acidosis.
Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.
Common questions
What are the most reported side effects of Metformin?
In FDA FAERS, the most frequently co-reported reaction terms for Metformin are diarrhoea, nausea, blood glucose increased, fatigue, acute kidney injury, lactic acidosis. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.
Does Metformin have an FDA boxed warning?
Yes. The current FDA label carries a boxed warning: LACTIC ACIDOSIS Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin-associated lactic acidosis is often subtle, accompanied only by nonspecific symptoms such as malaise, myalgias, respiratory distress, somnolence, and abdominal pain.
Do FAERS signals prove that Metformin causes these side effects?
No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.
Sources & methods
- FDA label via openFDA (set ID 7e41818c-60e9-4bcf-9586-7bb8d33d5e89, effective 20260615; matched on
openfda.generic_name.exact:"METFORMIN" AND openfda.product_type:"HUMAN PRESCRIPTION DRUG") - PubChem CID 4091 description (ChEBI)
- Bayesian shrinkage measures computed offline over all 1,317,300 cached pairs: BCPNN information component (IC, with Norén closed-form IC025) and MGPS empirical-Bayes geometric mean (EBGM, EB05) with a two-component gamma prior fitted by maximum marginal likelihood (α₁=0.57, β₁=0.02, α₂=1.42, β₂=0.70, w=0.17); unstratified
- FAERS pair statistics from the OpenPV build of 2026-09-14 (openFDA
count=aggregation, fieldpatient.drug.openfda.generic_name.exact, 1,153 reaction terms, min 3 co-reports); PRR/ROR with 95% CI, chi-square with Yates correction - Serious-only and stratified counts (serious:1, patient.patientsex, primarysource.qualification) from openFDA count queries; serious-only PRR uses the drug serious report total and the term global serious total (N_serious=11,882,979); strata shown only when n ≥ 20
- Seriousness and sex counts from openFDA
count=serious,patient.patientsex,seriousnessdeath - ClinicalTrials.gov API v2 (query
METFORMIN, results-bearing studies sorted by enrollment)
Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.